As part of a restructuring aimed at reducing cash operating expenses by 20%, bluebird bio will cut about 25% of its workforce, the company announced Sept. 24. The Somerville, Massachusetts–based biotech had 375 full-time employees—including 221 in R&D—as of June 30, according to a Sept. 13 SEC filing.
Bluebird expects to mostly complete its restructuring, which includes the layoffs, in the first quarter of next year, according to a Sept. 24 SEC filing.
https://www.biospace.com/job-trends/bluebird-bio-to-lay-off-25-of-workforce